Teachers Retirement System of The State of Kentucky Sells 916 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Teachers Retirement System of The State of Kentucky trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,975 shares of the medical equipment provider’s stock after selling 916 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Zimmer Biomet were worth $2,187,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. International Assets Investment Management LLC grew its position in shares of Zimmer Biomet by 11,244.9% in the 4th quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock valued at $8,146,000 after purchasing an additional 66,345 shares during the period. Sequoia Financial Advisors LLC increased its position in shares of Zimmer Biomet by 37.5% during the fourth quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock worth $18,981,000 after acquiring an additional 42,539 shares in the last quarter. TD Asset Management Inc increased its position in shares of Zimmer Biomet by 10.1% during the fourth quarter. TD Asset Management Inc now owns 169,595 shares of the medical equipment provider’s stock worth $20,640,000 after acquiring an additional 15,552 shares in the last quarter. Bank of Nova Scotia lifted its position in Zimmer Biomet by 499.0% in the 4th quarter. Bank of Nova Scotia now owns 134,729 shares of the medical equipment provider’s stock valued at $16,397,000 after acquiring an additional 112,237 shares in the last quarter. Finally, Premier Path Wealth Partners LLC acquired a new position in Zimmer Biomet in the 4th quarter worth $1,093,000. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on ZBH shares. The Goldman Sachs Group initiated coverage on Zimmer Biomet in a research note on Thursday, May 30th. They issued a “neutral” rating and a $129.00 price target on the stock. Oppenheimer boosted their target price on Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Barclays decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. Argus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a report on Tuesday, May 21st. Finally, Canaccord Genuity Group reiterated a “hold” rating and issued a $130.00 price target on shares of Zimmer Biomet in a research note on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $133.75.

Zimmer Biomet Stock Down 0.4 %

ZBH opened at $106.24 on Friday. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38. The stock’s fifty day simple moving average is $116.92 and its 200 day simple moving average is $121.54. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $147.50. The stock has a market cap of $21.86 billion, a PE ratio of 23.00, a price-to-earnings-growth ratio of 1.92 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.07. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company’s revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.89 earnings per share. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.90%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.